0000000000384345

AUTHOR

Ana-isabel Teruel

showing 2 related works from this author

Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

2020

On behalf of the PETHEMA/GEM Cooperative Group.

MaleOncologyPhysics::Instrumentation and Detectorsmedicine.medical_treatmentKaplan-Meier EstimateHematopoietic stem cell transplantationBiochemistryhemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsTumor MicroenvironmentProspective StudiesComputer Science::Operating SystemsIn Situ Hybridization FluorescenceMultiple myelomaRandomized Controlled Trials as TopicComputer Science::Cryptography and SecurityHazard ratioHematopoietic Stem Cell TransplantationHigh-Throughput Nucleotide SequencingHematologyMiddle AgedFlow CytometryPrognosisCombined Modality TherapyProgression-Free Survivalmedicine.anatomical_structureFemaleClonal HematopoiesisMultiple Myelomamedicine.medical_specialtyImmunologyTransplantation AutologousInternal medicinemedicineHumansClinical significanceProgression-free survivalComputer Science::Distributed Parallel and Cluster ComputingAgedAntineoplastic Combined Chemotherapy Protocolbusiness.industryCell Biologymedicine.diseaseTransplantationClinical Trials Phase III as TopicMyelodysplastic SyndromesMutationBone marrowbusinessMonoclonal gammopathy of undetermined significance
researchProduct

Matched-pairs analysis of outcomes with bortezomib, melphalan, and prednisone (VMP) treatment for previously untreated multiple myeloma (MM) using lo…

2015

(95% CI: 58-88%), respectively. A formal interim analysis of the Day 90 CR rate was conducted when 65 patients were evaluable, and at that time the Mel only arm was determined to be superior. The study was, therefore, stopped early by the Institutional DSMB. However, with a longer follow up Bu-Mel ultimately resulted in better PFS. Conclusions: Bu-Mel was associated with a significantly lower day 90 CR rate and a significantly higher rate of grade 3-4 non-hematologic toxicity, compared to Mel. However, after a median follow up of 15.7 months, PFS was significantly longer in the Bu-Mel arm. Figure 1 PFS from Day 90 by Treatment Arm

MelphalanCancer Researchmedicine.medical_specialtyLong term follow upbusiness.industryBortezomibUrologyHematologyInterim analysismedicine.diseasecarbohydrates (lipids)OncologyPrednisoneMedian follow-uphemic and lymphatic diseasesToxicitymedicinebusinessneoplasmsMultiple myelomamedicine.drugClinical Lymphoma Myeloma and Leukemia
researchProduct